What You Need to Know About Pharmacovigilance in Novel Hemophilia A Treatment - a podcast by ReachMD

CME credits: 0.25

Valid until: 31-03-2022

Claim your CME credit at https://reachmd.com/programs/cme/what-you-need-know-about-pharmacovigilance-novel-hemophilia-treatment/12331/

Pharmacovigilance begins after clinical trials end and new therapies enter everyday practice. Due to the rarity of hemophilia, participation in clinical trials has necessarily been small, and so monitoring the safety of new hemophilia treatments is especially important. Continued surveillance of adverse drug reactions (ADRs) after approval is a responsibility that falls on all members of the care team.

Dr. Shannon Meeks and Dr. Cindy Leissinger discuss the importance of safety surveillance and monitoring for novel hemophilia A therapeutics. To give a better understanding of pharmacovigilance, this activity includes animation that breaks down the process and illustrates where your ADR reports go and what happens next.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD